Back to search

Article

HLA-DQA1*05 Carriage is Associated with treatment failure and the induction of anti-IFX antibodies in IBD patients

2024-04-08

Abstract excerpt

<title>Abstract</title> <p>Repeated injections of anti-TNF may induce immunogenicity and loss of response to treatment in IBD (inflammatory bowel disease). An increased risk of immunogenicity in patients with the HLA-DQA1*05 phenotype has been already described. Here we selected 36 patients with IBD and follow the induction of anti-drug antibody according to their HLA phenotyping to individualize patients carryin...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
707f5dc8-a74c-5d4e-8e32-e4affdde0c8f
DOI
10.21203/rs.3.rs-4135820/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
HLA-DQA1*05 Carriage is Associated with treatment failure and the induction of anti-IFX antibodies in IBD patientsDOI 10.21203/rs.3.rs-4135820/v1
HLA-DQA1*05 is associated with the development of antibodies to anti-TNF therapySemantic proximity
Impact of HLA-DQA1*05 Genotype in Immunogenicity and Failure to Treatment with Tumour Necrosis Factor-alpha Antagonists in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.Semantic proximity
HLA-DQB1*03:01 and HLA-DQA1*05:05 as key genetic determinants of infliximab response and immunogenicity in Japanese patients with inflammatory bowel disease.Semantic proximity
Clinical utility of pre-treatment four-digit-resolution HLA genotyping to guide anti-tumor necrosis factor choice and concomitant immunomodulator use.Semantic proximity
Molecular Insight into the Role of HLA Genotypes in Immunogenicity and Secondary Refractoriness to Anti-TNF Therapy in IBD PatientsSemantic proximity
The HLA-DQA1*05 genotype does not influence the clinical response to ustekinumab and vedolizumab.Semantic proximity
Does HLA-DQA1*05 carriage have a greater impact on the outcome of infliximab therapy for isolated small-bowel Crohn's disease?Semantic proximity
HLADQA1*05 genotype predicts anti-drug antibody formation and loss of response during infliximab therapy for inflammatory bowel disease.Semantic proximity
Failure to Achieve Target Drug Concentrations During Induction and Not HLA-DQA1∗05 Carriage Is Associated With Antidrug Antibody Formation in Patients With Inflammatory Bowel Disease.Semantic proximity
Extended Analysis Identifies Drug-Specific Association of 2 Distinct HLA Class II Haplotypes for Development of Immunogenicity to Adalimumab and InfliximabSemantic proximity
HLA-DQA1∗05 Genotype and Immunogenicity to Tumor Necrosis Factor-α Antagonists: A Systematic Review and Meta-analysis.Semantic proximity
Influence of HLADQA1*05 Genotype in Adults With Inflammatory Bowel Disease and Anti-TNF Treatment With Proactive Therapeutic Drug Monitoring: A Retrospective Cohort Study.Semantic proximity
Select a neighboring publication to make it the new centre.